FDA approves lebrikizumab for atopic dermatitis in patients 12 years and older
The US Food and Drug Administration (FDA) has approved lebrikizumab (EBGLYSS) for the treatment of patients ≥12 years old with moderate to severe atopic dermatitis who meet weight and disease severity standards warranting potential benefit from the …